Goodwill and intangible assets acquired are recognized at fair value as of the acquisition date. The carrying amount of goodwill as of September 30, 2022 was $16.0 million. We have not recognized any impairment losses related to goodwill during the periods presented.

Intangible assets with definite lives are amortized over their estimated useful lives. The carrying basis and accumulated amortization of recognized intangible assets as of September 30, 2022 were as follows:


	Useful Life	Gross		Accumulated			Net Carrying
(In thousands)	(Years)	Amount		Amortization			Amount
Marketed products	8-10	$	152,500	$	(1,511	)	$	150,989
In-process research and development			72,100		—			72,100
Collaboration agreement			35,400		—			35,400
Total		$	260,000	$	(1,511	)	$	258,489

Intangible assets recognized as a result of the acquisition of Entasis amounted to $107.5 million, which consist of Entasis’ in-process research and development related to its antibacterial therapeutic product candidates and a collaboration agreement amounting to $72.1 million and $35.4 million, respectively. The useful lives of these intangible assets will be determined upon commercialization of the underlying product candidates; thus, no amortization expense of determinable assets was recognized during the period ended September 30, 2022.

Intangible assets recognized as a result of the acquisition of La Jolla amounting to $152.5 million pertain to product rights and developed technologies on La Jolla’s currently marketed products. These are intangible assets with determinable lives and are amortized over their estimated useful lives. We recognized amortization expense of $1.5 million for the three and nine months ended September 30, 2022. Future amortization expense is expected to be $3.5 million for the remainder of 2022, $13.8 million for each of the years from 2023 to 2026 and $78.0 million thereafter.